Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Letters3 April 2018Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin InjectionsRoy W. Beck, MD, PhD and Tonya D. Riddlesworth, PhDRoy W. Beck, MD, PhDJaeb Center for Health Research, Tampa, Florida (R.W.B., T.D.R.) and Tonya D. Riddlesworth, PhDJaeb Center for Health Research, Tampa, Florida (R.W.B., T.D.R.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0706 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:The treatment group difference used to calculate a sample size is the postulated estimate of the true population value and is not intended to indicate what would be considered clinically significant, which is a common misconception. The upper limit of the 95% CI for the observed treatment group difference in HbA1c levels was 0.6%, extending beyond the projected true population value of 0.4%. We believe that a treatment group difference of 0.3% represents a meaningful shift in the HbA1c distributions, as evidenced by our finding that 73% of the CGM group achieved an HbA1c reduction of 0.5% or ...References1. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55-73. [PMID: 28000140] doi:10.1007/s13300-016-0223-6 CrossrefMedlineGoogle Scholar2. U.S. Food and Drug Administration. Summary of safety and effectiveness data: Freestyle Libre Pro Flash Glucose Monitoring System. 2016. Accessed at www.accessdata.fda.gov/cdrh_docs/pdf15/p150021b.pdf on 28 October 2017. Google Scholar Author, Article, and Disclosure InformationAffiliations: Jaeb Center for Health Research, Tampa, Florida (R.W.B., T.D.R.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-2855. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoContinuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections Roy W. Beck , Tonya D. Riddlesworth , Katrina Ruedy , Andrew Ahmann , Stacie Haller , Davida Kruger , Janet B. McGill , William Polonsky , David Price , Stephen Aronoff , Ronnie Aronson , Elena Toschi , Craig Kollman , Richard Bergenstal , and Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections Thomas Haak Metrics Cited byIMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non‐insulin Antihyperglycaemic ThErapy ( IMMEDIATE ): A randomized controlled trialAcceptance and Effect of Continuous Glucose Monitoring on Discharge From Hospital in Patients With Type 2 Diabetes: Open-label, Prospective, Controlled StudyEpisodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled TrialPatients with Type 2 Diabetes and Residual Insulin Secretory Capacity Realize Glycemic Benefits from Real-Time Continuous Glucose MonitoringChange in Hemoglobin A1c and Quality of Life with Real-Time Continuous Glucose Monitoring Use by People with Insulin-Treated Diabetes in the Landmark StudyImproved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive AlertsDiabetes in ageing: pathways for developing the evidence base for clinical guidanceContinuous Glucose Monitoring: Review of an Innovation in Diabetes ManagementGoing beyond HbA1c to understand the benefits of advanced diabetes therapiesDigitale Tools und strukturierte Prozesse verbessern Therapiequalität 3 April 2018Volume 168, Issue 7Page: 526-527KeywordsBody weightDisclosureGlucoseHbA1cHypoglycemiaInsulinPatientsType 2 diabetesWeight gain ePublished: 3 April 2018 Issue Published: 3 April 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 8×
“Furthermore, there was no significant difference in CGM-measured hypoglycemia or quality-of-life outcomes (1).”
Influential
Cited by
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationThe fallacy of average: how using HbA1c alone to assess glycemic control can be misleading
Beck, R. W., Connor, C. G., Mullen, D. M., Wesley, D. M., & Bergenstal, R. M. (2017) · Diabetes Care · doi:10.2337/dc17-0636 · Cited by 477
Self-citationContinuous Glucose Monitoring: Review of an Innovation in Diabetes Management
Mian, Z., Hermayer, K. L., & Jenkins, A. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.07.003 · Cited by 139
Aronson, R., Brown, R. E., Chu, L., Bajaj, H. S., Khandwala, H., Abitbol, A., Malakieh, N., & Goldenberg, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14949 · Cited by 118
“rtCGM is similarly useful in individuals with type 2 diabetes using intensive insulin therapy.(3) The MOBILE study recently extended those findings to individuals using only basal insulin therapy, who achieved a 0.”
MethodPrice, D. A., Deng, Q., Kipnes, M., & Beck, S. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01086-y · Cited by 77
Metadata
- Authors
- Beck, R. W., & Riddlesworth, T. D.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-04-03
- Volume
- 168
- Issue
- 7
- Pages
- 526-527
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2990064316
- Cited by
- 26
- References
- 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. https://app.cochat.ai/papers/10.7326/l17-0706
- The paper
- Beck, R. W., & Riddlesworth, T. D. (2018). Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections. Annals of Internal Medicine. https://doi.org/10.7326/l17-0706
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.